中國生物製藥(01177.HK)將於歐洲呼吸學會年會公布四項研究結果
中國生物製藥(01177.HK)公布,集團開發的「TQC3721(PDE3/4抑制劑)」、「TQC2731(TSLP單抗)」、「TQC3403(烏美溴銨維蘭特羅吸入粉霧劑)」將於9月27日至10月1日舉行的2025年歐洲呼吸學會年會 (ERS 2025)公布4項研究成果。
TQC3721是一款全新機制的吸入性PDE3/4抑制劑,具有擴張支氣管和抗炎的雙重作用,目前正在國內開展Ⅲ期臨床試驗。TQC2731是一款抗TSLP的人源化單克隆抗體,可以減少哮喘急性發作,目前全球僅一款TSLP單抗獲批上市。TQC3403是一款吸入粉霧劑,通過雙重作用機制實現長效支氣管擴張,有望在2026年上半年獲批上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.